Andrew Belch

720 total citations
11 papers, 360 citations indexed

About

Andrew Belch is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Andrew Belch has authored 11 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Pathology and Forensic Medicine and 4 papers in Oncology. Recurrent topics in Andrew Belch's work include Lymphoma Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (2 papers) and Sarcoma Diagnosis and Treatment (2 papers). Andrew Belch is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Acute Myeloid Leukemia Research (2 papers) and Sarcoma Diagnosis and Treatment (2 papers). Andrew Belch collaborates with scholars based in Canada and Japan. Andrew Belch's co-authors include C. Tom Kouroukis, Randy D. Gascoyne, Elizabeth A. Eisenhauer, Michael Crump, Robert Turner, Jean Powers, Ralph M. Meyer, Reinhard Lohmann, Joseph M. Connors and Pedro López and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Andrew Belch

11 papers receiving 345 citations

Peers

Andrew Belch

ONCOL

PFM

GENET

PRM

E. Jane Leonard United States

RM Braziel United States

Eivind Galteland Norway

Danielle Shafer United States

JR Downing United States

Elena Ruíz-Ballesteros Spain

Thomas F.E. Barth Germany

Luca Vincenzo Cappelli Italy

Matko Kalac United States

Yoshiaki Chinen Japan

E. Jane Leonard United States

Andrew Belch

206 ×1.0

ONCOL

116 ×0.9

PFM

166 ×1.7

77 ×0.8

GENET

53 ×0.7

PRM

Citations per year, relative to Andrew Belch Andrew Belch (= 1×) peers E. Jane Leonard

Countries citing papers authored by Andrew Belch

Since Specialization

Citations

This map shows the geographic impact of Andrew Belch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Belch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Belch more than expected).

Fields of papers citing papers by Andrew Belch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Belch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Belch. The network helps show where Andrew Belch may publish in the future.

Co-authorship network of co-authors of Andrew Belch

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Belch. A scholar is included among the top collaborators of Andrew Belch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Belch. Andrew Belch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Zheng, Mei, Lawrence Rosen, David Gordon, et al.. (2005). P104 Continuing benefit of zoledronic acid for the prevention of skeletal complications in breast cancer patients with bone metastases. The Breast. 14. S44–S44. 6 indexed citations

Keats, Jonathan J., Christopher A. Maxwell, Tony Reiman, et al.. (2004). Altered Kinetics and Localization of MMSET Variants Suggests That RE-IIBP Overexpression Is a Unifying Event in t(4;14)(p16;q32) Multiple Myeloma.. Blood. 104(11). 75–75. 3 indexed citations

Belch, Andrew, C. Tom Kouroukis, Michael Crump, et al.. (2004). Phase II Trial of Bortezomib in Mantle Cell Lymphoma.. Blood. 104(11). 608–608. 27 indexed citations

Marcus, Robert, Kevin Imrie, Andrew Belch, et al.. (2003). An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma.. Ghent University Academic Bibliography (Ghent University). 34 indexed citations

Kouroukis, C. Tom, Andrew Belch, Michael Crump, et al.. (2003). Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 21(9). 1740–1745. 215 indexed citations

Urtasun, Raul C., et al.. (1998). Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study. International Journal of Radiation Oncology*Biology*Physics. 40(2). 337–342. 15 indexed citations

Keating, Armand, et al.. (1996). Treatment of acute myeloid leukemia (AML) at diagnosis in 99 unselected adults with high dose ARA-C (HIDAC) and mitoxantrone: Long-term follow-up.. Blood. 88(10). 833–833. 1 indexed citations

Palmer, Matthew, Aik Seng Ng, Kevin Dietrich, et al.. (1991). Elevated c-myc messenger RNA in multiple myeloma cell lines.. PubMed. 8(3). 117–24. 3 indexed citations

Brox, Larry W., et al.. (1985). Single-strand breaks or alkali-sensitive sites in the DNA of human myeloma plasma cells and chronic lymphocytic leukemia lymphocytes. Canadian Journal of Biochemistry and Cell Biology. 63(9). 977–981. 3 indexed citations

10.

Minden, Mark D., Hans A. Messner, & Andrew Belch. (1985). Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment length polymorphism.. Journal of Clinical Investigation. 75(1). 91–93. 28 indexed citations

11.

Belch, Andrew, et al.. (1980). Hemolysis in mice treated with deoxycoformycin, am inhibitor of adenosine deaminase. Biochemical Pharmacology. 29(8). 1209–1210. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact